Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections

ST. LOUIS, Dec. 6, 2018 /PRNewswire/ -- Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). This novel drug candidate represents a new strategy for treating bacterial infections by preventing the bacteria that cause UTIs from sticking to the walls of the bladder, thus allowing the body to naturally eliminate the infection. Since this mannose-containing compound does not kill bacteria, it potentially could treat and prevent UTIs without inducing antibiotic resistance. "We are thrilled to have hit this candidate selection milestone with GSK," Dr. Scott Hultgren, co-founder and board member of Fimbrion, said. About DPAC - Discovery Partnerships with Academia (DPAc) is an innovative approach to drug discovery. As a unit within GSK's research and development organization, DPAc is dedicated to creating highly collaborative relationships with leading academic researchers to develop new medicines that truly benefit patients.

First found on: www.prnewswire.co.uk And then on: 1 other references